Evidence map›Paper›PMID 34441977›Full record

ReviewJournal of clinical medicine2021

Diabetes Mellitus and Heart Failure.

Filippos Triposkiadis, Andrew Xanthopoulos, Alexandra Bargiota, Takeshi Kitai, Niki Katsiki, Dimitrios Farmakis, John Skoularigis, Randall C Starling, Efstathios Iliodromitis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. The immunology of diabetic cardiomyopathy.Frontiers in endocrinology · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Filippos TriposkiadisDepartment of Cardiology, University General Hospital of Larissa, 411 10 Larissa, Greece.ORCID 0000-0001-6433-4016
Andrew XanthopoulosDepartment of Cardiology, University General Hospital of Larissa, 411 10 Larissa, Greece.ORCID 0000-0002-9439-3946
Alexandra BargiotaDepartment of Endocrinology and Metabolic Diseases, University General Hospital of Larissa, 411 10 Larissa, Greece.
Takeshi KitaiNational Cerebral and Cardiovascular Center, Osaka 564-8565, Japan.ORCID 0000-0003-2416-5865
Niki KatsikiSecond Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 54124 Thessaloniki, Greece.
Dimitrios FarmakisUniversity of Cyprus Medical School, P.O. Box 20537, Nicosia 1678, Cyprus.
John SkoularigisDepartment of Cardiology, University General Hospital of Larissa, 411 10 Larissa, Greece.
Randall C StarlingKaufman Center for Heart Failure Treatment and Recovery, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Efstathios IliodromitisSecond Department of Cardiology, National and Kapodistrian University of Athens, Attikon University Hospital, 12462 Athens, Greece.
University Hospital of Larissa · GRAristotle University of Thessaloniki · GRCleveland Clinic · USNational and Kapodistrian University of Athens · GRNational Cerebral and Cardiovascular Center · JPUniversity of Cyprus · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is a major risk factor for new-onset heart failure (HF) and vice versa. The pathogenesis of new-onset HF in DM is complex and has been largely attributed to the toxic cardiovascular effects of hyperglycemia and relevant metabolic abnormalities (diabetic cardiomyopathy) as well as the frequently coexisting morbidities such as hypertension (HTN), coronary artery disease (CAD), and diabetic nephropathy. In patients with type 1 DM (T1DM), HF develops in the setting of a dysregulated immune response, whereas in most patients with type 2 DM (T2DM), against a background of overweight/obesity. HF prevention in DM is feasible with rigorous treatment of cardiovascular risk factors and selective antidiabetic agents. Conversely, development of new-onset T2DM in HF (cardiogenic DM) is common and has been attributed to an increase in the resistance to insulin, especially in the skeletal muscle, liver, and adipose tissue as well as in diminished insulin secretory response to hyperglycemia by pancreatic β-cells. Cardiogenic DM further deteriorates cardiac dysfunction and adversely affects outcome in HF. Novel lifesaving medications employed in HF management such as sacubitril/valsartan and sodium glucose cotransporter 2 inhibitors (SGLT-2i) have a favorable metabolic profile and lower the incidence of cardiogenic diabetes. Whether mitigation of cardiogenic DM should be a treatment target in HF deserves further investigation.

Indexed as

diabetesdiabetic cardiomyopathyheart failure

Identifiers

PMID34441977
PMCPMC8396967
OpenAlexW3195557959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.